This website uses cookies
Read our Privacy policy and Terms of use for more information.
Sep 22, 2026
Anthropic confirms a biology wet lab, Telix agrees to buy ITM for up to $2.35B, and Lilly wins a new breast-cancer combination approval.
Sep 17, 2026
FDA opens expedited IND pilot to speed U.S. trials as Novartis, GSK and Lilly spend on brain delivery, antibodies and genetic medicine.
Sep 15, 2026
Novo unveils a brand and culture reset while Scholar Rock wins FDA approval in SMA, GSK and Roche-backed ADCs improve survival, and Definium moves toward a filing.
Sep 10, 2026
A $12B biotech deal meets Phase 3 reality, while semaglutide moves into younger children and an AI-discovered drug gets an aging-clock analysis.
Sep 8, 2026
Ultragenyx shares plunge 44% after its Angelman drug misses both Phase 3 endpoints. Plus, FDA trial scrutiny and major biotech deals.
Sep 3, 2026
Novartis pauses eight autoimmune CAR-T trials after three deaths, while Roche, Medtronic and Big Pharma keep dealmaking at full speed.
Sep 1, 2026
Lilly bets up to $2.875B on Merida, BioNTech ends a colorectal cancer vaccine trial, and Mounjaro adds a cardiovascular-risk indication.
Aug 27, 2026
FDA approves Revolution Medicines’ Rasonque after it extends median survival from 6.7 to 13.2 months in metastatic pancreatic cancer, plus biotech deal news.
Aug 25, 2026
Merck and Moderna’s mRNA cancer vaccine wins Phase 3 as FDA approves Genglycos and puts Regenxbio’s RGX-121 back on hold.
